The importance of surgical and multimodality treatment for small cell bronchial carcinoma

Effect of Chemotherapy in Patients With Resected Small-Cell or Large-Cell Neuroendocrine Carcinoma

“…In most published studies, the survival benefit associated with surgery is limited to stage I and II disease. 18,19,31,32,17,20,30 This is concordant with our observations. In our series, 80% of patients in the group surgery plus perioperative treatment (chemotherapy, radiotherapy, or both) were stage I or II.…”

Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: The Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101)

“…Indications for surgical resection for SCLC have not yet been determined, although several authors have reported that a small minority of patients with limited-stage disease and adequate lung function might benefit from surgical resection. [1][2][3][4][5][6][7][8][9] According to these reports, the prognosis of resected SCLC was not so poor, especially when no pathologic nodal involvement was observed. The 5-year survival ranged from 26% to 61% in these trials if the tumor was stage I.…”

Indication for Surgery in Small-cell Carcinoma of the Lung

“…We were able to obtai n a 3-year-survival rate of 45 % in stage II. As for the influence of neoadjuvan t chemother apy, since only 4 out of 7 patien ts in our study rece ived neoadjuvant che motherapy no sta te ment can mad e. Karr er et al achieved a 3-yearsurvival rat e of 35 % in tumor stage II after surgery and chemo therapy without neoadjuva nt che motherapy (17,18,42) . Our prospective 3 yea r survival rate of 38 % in tumor stage IIIa confirmed the success of surgery in N2 tumors.…”